1-[3-(Trifluoromethyl)phenyl]piperazine (BioDeep_00000172908)

 

Secondary id: BioDeep_00001901144

human metabolite blood metabolite


代谢物信息卡片


N-(alpha,alpha,alpha-Trifluoro-3-tolyl)piperazine

化学式: C11H13F3N2 (230.1031)
中文名称: 1-(3-三氟甲基苯基)哌嗪
谱图信息: 最多检出来源 Homo sapiens(blood) 55.08%

分子结构信息

SMILES: C1CN(CCN1)C2=CC=CC(=C2)C(F)(F)F
InChI: InChI=1S/C11H13F3N2/c12-11(13,14)9-2-1-3-10(8-9)16-6-4-15-5-7-16/h1-3,8,15H,4-7H2

描述信息

D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists

同义名列表

9 个代谢物同义名

N-(alpha,alpha,alpha-Trifluoro-3-tolyl)piperazine; 1-[3-(Trifluoromethyl)phenyl]piperazine; 1-(3-Trifluoromethylphenyl)piperazine; N-(Α,α,α-trifluoro-3-tolyl)piperazine; 1-(m-Trifluoromethylphenyl)piperazine; N-(a,a,a-Trifluoro-3-tolyl)piperazine; N-(3-Trifluoromethylphenyl)piperazine; 3-Trifluoromethylphenylpiperazine; TFMPP



数据库引用编号

8 个数据库交叉引用编号

分类词条

相关代谢途径

Reactome(0)

BioCyc(0)

PlantCyc(0)

代谢反应

0 个相关的代谢反应过程信息。

Reactome(0)

BioCyc(0)

WikiPathways(0)

Plant Reactome(0)

INOH(0)

PlantCyc(0)

COVID-19 Disease Map(0)

PathBank(0)

PharmGKB(0)

1 个相关的物种来源信息

在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：

  • PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
  • NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
  • Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
  • Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。

点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。

亚细胞结构定位 关联基因列表


文献列表

  • Yifei Ren, Junyi Du, Xianchao Du, Guobin Xin, Jing Chang, Hong Zhou, Hongxia Hao. A novel analytical method of TFMPP and mCPP in fluids of drug addicts using LLE-GC/NPD. Technology and health care : official journal of the European Society for Engineering and Medicine. 2019; 27(S1):67-84. doi: 10.3233/thc-199008. [PMID: 31045528]
  • Marcelo Dutra Arbo, Simone Melega, Regina Stöber, Markus Schug, Eugen Rempel, Jörg Rahnenführer, Patricio Godoy, Raymond Reif, Cristina Cadenas, Maria de Lourdes Bastos, Helena Carmo, Jan G Hengstler. Hepatotoxicity of piperazine designer drugs: up-regulation of key enzymes of cholesterol and lipid biosynthesis. Archives of toxicology. 2016 Dec; 90(12):3045-3060. doi: 10.1007/s00204-016-1665-3. [PMID: 26821219]
  • Magdalene H Y Tang, C K Ching, M L Tse, Carol Ng, Caroline Lee, Y K Chong, Watson Wong, Tony W L Mak. Surveillance of emerging drugs of abuse in Hong Kong: validation of an analytical tool. Hong Kong medical journal = Xianggang yi xue za zhi. 2015 Apr; 21(2):114-23. doi: 10.12809/hkmj144398. [PMID: 25756277]
  • Michael H Baumann, Simon Bulling, Tova S Benaderet, Kusumika Saha, Mario A Ayestas, John S Partilla, Syed F Ali, Thomas Stockner, Richard B Rothman, Walter Sandtner, Harald H Sitte. Evidence for a role of transporter-mediated currents in the depletion of brain serotonin induced by serotonin transporter substrates. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. 2014 May; 39(6):1355-65. doi: 10.1038/npp.2013.331. [PMID: 24287719]
  • Robert D Johnson, Sabra R Botch-Jones. The stability of four designer drugs: MDPV, mephedrone, BZP and TFMPP in three biological matrices under various storage conditions. Journal of analytical toxicology. 2013 Mar; 37(2):51-5. doi: 10.1093/jat/bks138. [PMID: 23325764]
  • I E D Moreno, B M da Fonseca, M Barroso, S Costa, J A Queiroz, E Gallardo. Determination of piperazine-type stimulants in human urine by means of microextraction in packed sorbent and high performance liquid chromatography-diode array detection. Journal of pharmaceutical and biomedical analysis. 2012 Mar; 61(?):93-9. doi: 10.1016/j.jpba.2011.12.004. [PMID: 22221903]
  • I E D Moreno, B M da Fonseca, A R Magalhães, V S Geraldes, J A Queiroz, M Barroso, S Costa, E Gallardo. Rapid determination of piperazine-type stimulants in human urine by microextraction in packed sorbent after method optimization using a multivariate approach. Journal of chromatography. A. 2012 Jan; 1222(?):116-20. doi: 10.1016/j.chroma.2011.12.016. [PMID: 22209305]
  • Mitsuhiro Wada, Kozue Yamahara, Rie Ikeda, Ruri Kikura-Hanajiri, Naotaka Kuroda, Kenichiro Nakashima. Simultaneous determination of N-benzylpiperazine and 1-(3-trifluoromethylphenyl)piperazine in rat plasma by HPLC-fluorescence detection and its application to monitoring of these drugs. Biomedical chromatography : BMC. 2012 Jan; 26(1):21-5. doi: 10.1002/bmc.1619. [PMID: 21387353]
  • Mark Baron, Mathieu Elie, Leonie Elie. An analysis of legal highs: do they contain what it says on the tin?. Drug testing and analysis. 2011 Sep; 3(9):576-81. doi: 10.1002/dta.274. [PMID: 21595051]
  • Charlotte Bell, Claire George, Andrew T Kicman, Allan Traynor. Development of a rapid LC-MS/MS method for direct urinalysis of designer drugs. Drug testing and analysis. 2011 Jul; 3(7-8):496-504. doi: 10.1002/dta.306. [PMID: 21744513]
  • Mitsuhiro Wada, Keisuke Abe, Rie Ikeda, Ruri Kikura-Hanajiri, Naotaka Kuroda, Kenichiro Nakashima. HPLC determination of methylphenidate and its metabolite, ritalinic acid, by high-performance liquid chromatography with peroxyoxalate chemiluminescence detection. Analytical and bioanalytical chemistry. 2011 Apr; 400(2):387-93. doi: 10.1007/s00216-011-4713-0. [PMID: 21318251]
  • Leo J Schep, Robin J Slaughter, J Allister Vale, D Michael G Beasley, Paul Gee. The clinical toxicology of the designer "party pills" benzylpiperazine and trifluoromethylphenylpiperazine. Clinical toxicology (Philadelphia, Pa.). 2011 Mar; 49(3):131-41. doi: 10.3109/15563650.2011.572076. [PMID: 21495881]
  • Barry K Logan, Anthony G Costantino, Eric F Rieders, David Sanders. Trazodone, meta-chlorophenylpiperazine (an hallucinogenic drug and trazodone metabolite), and the hallucinogen trifluoromethylphenylpiperazine cross-react with the EMIT®II ecstasy immunoassay in urine. Journal of analytical toxicology. 2010 Nov; 34(9):587-9. doi: 10.1093/jat/34.9.587. [PMID: 21073812]
  • Amber J Dickson, Shawn P Vorce, Justin M Holler, Timothy P Lyons. Detection of 1-benzylpiperazine, 1-(3-trifluoromethylphenyl)-piperazine, and 1-(3-chlorophenyl)-piperazine in 3,4-methylenedioxymethamphetamine-positive urine samples. Journal of analytical toxicology. 2010 Oct; 34(8):464-9. doi: 10.1093/jat/34.8.464. [PMID: 21819791]
  • Ushtana Antia, Malcolm D Tingle, Bruce R Russell. Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma and its application to the pharmacokinetic study of TFMPP in humans. Journal of forensic sciences. 2010 Sep; 55(5):1311-8. doi: 10.1111/j.1556-4029.2010.01457.x. [PMID: 20533987]
  • Ushtana Antia, Malcolm D Tingle, Bruce R Russell. In vivo interactions between BZP and TFMPP (party pill drugs). The New Zealand medical journal. 2009 Sep; 122(1303):29-38. doi: NULL. [PMID: 19851418]
  • David M Wood, Jenny Button, Satnam Lidder, John Ramsey, David W Holt, Paul I Dargan. Dissociative and sympathomimetic toxicity associated with recreational use of 1-(3-trifluoromethylphenyl) piperazine (TFMPP) and 1-benzylpiperzine (BZP). Journal of medical toxicology : official journal of the American College of Medical Toxicology. 2008 Dec; 4(4):254-7. doi: 10.1007/bf03161209. [PMID: 19031377]
  • Shawn P Vorce, Justin M Holler, Barry Levine, Marilyn R Past. Detection of 1-benzylpiperazine and 1-(3-trifluoromethylphenyl)-piperazine in urine analysis specimens using GC-MS and LC-ESI-MS. Journal of analytical toxicology. 2008 Jul; 32(6):444-50. doi: 10.1093/jat/32.6.444. [PMID: 18652752]
  • Simon Elliott, Christopher Smith. Investigation of the first deaths in the United Kingdom involving the detection and quantitation of the piperazines BZP and 3-TFMPP. Journal of analytical toxicology. 2008 Mar; 32(2):172-7. doi: 10.1093/jat/32.2.172. [PMID: 18334102]
  • Hiroe Tsutsumi, Munehiro Katagi, Akihiro Miki, Noriaki Shima, Tooru Kamata, Mayumi Nishikawa, Kunio Nakajima, Hitoshi Tsuchihashi. Development of simultaneous gas chromatography-mass spectrometric and liquid chromatography-electrospray ionization mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences. 2005 May; 819(2):315-22. doi: 10.1016/j.jchromb.2005.02.016. [PMID: 15833296]
  • H Tsutsumi, M Katagi, A Miki, N Shima, T Kamata, K Nakajima, H Inoue, T Kishi, H Tsuchihashi. Isolation, identification and excretion profile of the principal urinary metabolite of the recently banned designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP) in rats. Xenobiotica; the fate of foreign compounds in biological systems. 2005 Jan; 35(1):107-16. doi: 10.1080/00498250400020335. [PMID: 15788372]
  • Roland F Staack, Liane D Paul, Dietmar Springer, Thomas Kraemer, Hans H Maurer. Cytochrome P450 dependent metabolism of the new designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP). In vivo studies in Wistar and Dark Agouti rats as well as in vitro studies in human liver microsomes. Biochemical pharmacology. 2004 Jan; 67(2):235-44. doi: 10.1016/j.bcp.2003.08.029. [PMID: 14698036]
  • Roland F Staack, Gieselher Fritschi, Hans H Maurer. New designer drug 1-(3-trifluoromethylphenyl) piperazine (TFMPP): gas chromatography/mass spectrometry and liquid chromatography/mass spectrometry studies on its phase I and II metabolism and on its toxicological detection in rat urine. Journal of mass spectrometry : JMS. 2003 Sep; 38(9):971-81. doi: 10.1002/jms.513. [PMID: 14505325]
  • G E Pickard, B N Smith, M Belenky, M A Rea, F E Dudek, P J Sollars. 5-HT1B receptor-mediated presynaptic inhibition of retinal input to the suprachiasmatic nucleus. The Journal of neuroscience : the official journal of the Society for Neuroscience. 1999 May; 19(10):4034-45. doi: 10.1523/jneurosci.19-10-04034.1999. [PMID: 10234032]
  • R E Poland, P Lutchmansingh, S McGeoy, D Au, M Que, S Acosta, M Edelstein, J T McCracken. Prenatal stress prevents the desensitization of the corticosterone response to TFMPP by desmethylimipramine, but not by phenelzine, in adult male offspring. Life sciences. 1995; 57(23):2163-70. doi: 10.1016/0024-3205(95)02208-z. [PMID: 7475968]
  • Y Shen, F J Monsma, M A Metcalf, P A Jose, M W Hamblin, D R Sibley. Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype. The Journal of biological chemistry. 1993 Aug; 268(24):18200-4. doi: . [PMID: 8394362]
  • J Rouru, U Pesonen, K Isaksson, R Huupponen, M Koulu. Effect of chronic treatment with TFMPP, a 5-HT1 receptor agonist, on food intake, weight gain, plasma insulin and neuropeptide mRNA expression in obese Zucker rats. European journal of pharmacology. 1993 Apr; 234(2-3):191-8. doi: 10.1016/0014-2999(93)90953-f. [PMID: 8482326]
  • N Adham, H T Kao, L E Schecter, J Bard, M Olsen, D Urquhart, M Durkin, P R Hartig, R L Weinshank, T A Branchek. Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase. Proceedings of the National Academy of Sciences of the United States of America. 1993 Jan; 90(2):408-12. doi: 10.1073/pnas.90.2.408. [PMID: 8380639]
  • C D Unsworth, P B Molinoff. Regulation of the 5-hydroxytryptamine1B receptor in opossum kidney cells after exposure to agonists. Molecular pharmacology. 1992 Sep; 42(3):464-70. doi: NULL. [PMID: 1328846]
  • R E Poland, A Frazer. Corticosterone and prolactin response to TFMPP in rats during repeated antidepressant administration. The Journal of pharmacy and pharmacology. 1991 Jan; 43(1):54-6. doi: 10.1111/j.2042-7158.1991.tb05450.x. [PMID: 1676062]
  • F Chaouloff, D Laude, V Baudrie. Effects of the 5-HT1C/5-5-HT2 receptor agonists DOI and alpha-methyl-5-HT on plasma glucose and insulin levels in the rat. European journal of pharmacology. 1990 Oct; 187(3):435-43. doi: 10.1016/0014-2999(90)90370-l. [PMID: 2127400]
  • A Di Sciullo, M T Bluet-Pajot, F Mounier, C Oliver, B Schmidt, C Kordon. Changes in anterior pituitary hormone levels after serotonin 1A receptor stimulation. Endocrinology. 1990 Aug; 127(2):567-72. doi: 10.1210/endo-127-2-567. [PMID: 2164913]
  • R W Fuller, H D Snoddy, B B Molloy. Central serotonin agonist actions of LY 165163, 1-(m-trifluoromethylphenyl)-4-(p-aminophenylethyl) piperazine, in rats. The Journal of pharmacology and experimental therapeutics. 1986 Nov; 239(2):454-9. doi: NULL. [PMID: 2430093]
  • J A Clemens, M E Roush. Inhibition of prolactin release by stimulation of presynaptic serotonin autoreceptors. Life sciences. 1982 Dec; 31(23):2641-6. doi: 10.1016/0024-3205(82)90740-8. [PMID: 7154858]
  • K Hashimoto, N Ohno, K Murakami, J Kageyama, Y Aoki, J Takahara. The effect of serotonin agonist 1-(trifluoromethylphenyl)-piperazine on corticotropin releasing factor and arginine vasopressin in rat hypothalamic nuclei. Endocrinologia japonica. 1982 Jun; 29(3):383-8. doi: 10.1507/endocrj1954.29.383. [PMID: 6293810]
  • L Giuliani, G Carmignani, E Belgrano, P Puppo. Transcatheter arterial embolization in urological tumors: the use of isobutyl-2-cyanoacrylate. The Journal of urology. 1979 May; 121(5):630-4. doi: 10.1016/s0022-5347(17)56913-x. [PMID: 439260]
  • J Watkins, A Padfield, J D Alderson. Underlying immunopathology as a cause of adverse responses to two intravenous anaesthetic agents. British medical journal. 1978 May; 1(6121):1180-1. doi: 10.1136/bmj.1.6121.1180. [PMID: 638678]
  • A C Buck. Disorders of micturition in bacterial prostatitis. Proceedings of the Royal Society of Medicine. 1975 Aug; 68(8):508-11. doi: NULL. [PMID: 681]